PLEASANTON, Calif.—The Cooper Companies, Inc. (NYSE:COO) announced financial results for the fiscal second quarter ended April 30, 2010. Revenue increased 11 percent year-over-year to $289.3 million. CooperVision (CVI) revenue was up 11 percent to $242.3 million, and CooperSurgical (CSI) revenues rose 10 percent to $47.0 million for the period.

Commenting on the results, Robert S. Weiss, Cooper's president and CEO said, "We delivered a very strong second quarter across our vision and surgical businesses. Both businesses posted double-digit revenue growth, and we remain committed to investing in our sales and marketing efforts to continue gaining market share. Overall, we are pleased with our financial results, especially our trailing four quarter free cash flow of $218.2 million, and we believe CooperVision and CooperSurgical are well positioned for future growth."

In the CooperVision (CVI) business, the company noted revenue gains in all product categories and regions. Revenue $242.3 million, up 11% from last year's second quarter, up 10 percent in constant currency. Revenue gains were delivered throughout all product categories and geographic regions, including a 13 percent gain in the Americas. The company said that its Proclear lens revenues for the period, which represent 29 percent of CVI revenues, were up 17 percent, to $69.5 million for the period, while its silicone hydrogel products sales, which now account for 22 percent of CVI revenues, rose 156 percent from the comparable period last year to reach $54 million.

A transcript of a conference call with the Q2 results will be posted at www.coopercos.com.